
    
      An open label, multi centre, three arm, dose finding Phase 1 trial with Forodesine as a
      single drug treatment in patients with relapsed CLL to establish dose and duration of
      treatment resulting in the best achievable response with Forodesine as a single drug
      treatment.
    
  